Evidence map›Paper›PMID 27443516›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2016

CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma.

Elisabetta Kuhn, Tian-Li Wang, Kai Doberstein, Asli Bahadirli-Talbott, Ayse Ayhan, Ann Smith Sehdev, Ronny Drapkin, Robert J Kurman, Ie-Ming Shih

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 2 pooled it
15.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Molecular Management of High-Grade Serous Ovarian Carcinoma.International journal of molecular sciences · 2022
    Review
  18. Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Elisabetta KuhnDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Tian-Li WangDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Kai DobersteinDepartment of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA.
Asli Bahadirli-TalbottDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Ayse AyhanDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Ann Smith SehdevLegacy Health Systems, Portland, OR, USA.
Ronny DrapkinDepartment of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-6912-6977
Robert J KurmanDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Ie-Ming ShihDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Johns Hopkins University · USCancer Research Center · USLegacy Health · US

Funding

Tumor Suppressor Role of ARID1AR21CA165807 · NCI · JOHNS HOPKINS UNIVERSITY · PI SHIH, IE-MING · 2012 to 2013
$375k
NCI NIH HHS R21 CA165807
6 · The paper itself

Abstract

Aberration in chromosomal structure characterizes almost all cancers and has profound biological significance in tumor development. It can be facilitated by various mechanisms including overexpression of cyclin E1 and centrosome amplification. As ovarian high-grade serous carcinoma has pronounced chromosomal instability, in this study we sought to determine whether increased copy number of CCNE1 which encodes cyclin E1 and centrosome amplification (>2 copies) occurs in its putative precursor, serous tubal intraepithelial carcinoma. We found CCNE1 copy number gain/amplification in 8 (22%) of 37 serous tubal intraepithelial carcinomas and 12 (28%) of 43 high-grade serous carcinomas. There was a correlation in CCNE1 copy number between serous tubal intraepithelial carcinoma and high-grade serous carcinoma in the same patients (P<0.001). There was no significant difference in the percentage of CCNE1 gain/amplification between serous tubal intraepithelial carcinoma and high-grade serous carcinoma (P=0.61). Centrosome amplification was recorded in only 5 (14%) of 37 serous tubal intraepithelial carcinomas, and in 10 (40%) of 25 high-grade serous carcinomas. The percentage of cells with centrosome amplification was higher in high-grade serous carcinoma than in serous tubal intraepithelial carcinoma (P<0.001). Induced expression of cyclin E1 increased the percentage of fallopian tube epithelial cells showing centrosome amplification. Our findings suggest that gain/amplification of CCNE1 copy number occurs early in tumor progression and precedes centrosome amplification. The more prevalent centrosome amplification in high-grade serous carcinoma than in serous tubal intraepithelial carcinoma supports the view that serous tubal intraepithelial carcinoma precedes the development of many high-grade serous carcinomas.

Indexed as

Gene AmplificationCarcinoma in SituCentrosomeCyclin ECystadenocarcinoma, SerousFallopian Tube NeoplasmsFemaleHumansMiddle AgedNeoplasm GradingOncogene ProteinsOvarian NeoplasmsCCNE1 protein, humanCyclin EOncogene Proteins

Identifiers

PMID27443516
PMCPMC6557162
OpenAlexW2479970996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.